Varenicline Plus Nicotine Patch Didn’t Improve Smoking Cessation

Varenicline plus nicotine patch therapy was not associated with greater tobacco smoking cessation than varencline monotherapy in adults who smoke cigarettes, according to research findings.

The double-blind study included 1251 adults (mean age, 49.1 years; 54.0% women) who smoked 5 or more cigarettes per day during the last 6 months of enrollment.

Participants underwent cessation counseling and were randomly assigned to receive either varenicline monotherapy for a total of 12 weeks (n=315), a 12-week course of combination therapy comprising varenicline plus nicotine patch (n=314), varenicline monotherapy for 24 weeks (n=311), or the same combination regimen of varenicline plus nicotine patch for 24 weeks (n=311).

Get the full story at pulmonologyadvisor.com

---

Varenicline Plus Nicotine Patch

Go To Source For Respiratory Therapy Coverage

RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.

Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.